



## Clinical trial results:

**Does perineural clonidin prolong the duration of an adductor canal block when controlling for a systemic effect?**

**- a randomized, blinded, paired study in healthy volunteers.**

### Summary

EudraCT number	2014-005640-18
Trial protocol	DK
Global end of trial date	30 June 2015

### Results information

Result version number	v1 (current)
This version publication date	11 January 2022
First version publication date	11 January 2022

### Trial information

#### Trial identification

Sponsor protocol code	SM1-JH-14
-----------------------	-----------

#### Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	-
WHO universal trial number (UTN)	-

Notes:

### Sponsors

Sponsor organisation name	Zealand University Hospital
Sponsor organisation address	Lykkebaekvej 1, Koege, Denmark, 4600
Public contact	Clinical trials information, Køge Sygehus, 0045 60610666, Hessel@dadlnet.dk
Scientific contact	Clinical trials information, Køge Sygehus, 0045 60610666, Hessel@dadlnet.dk

Notes:

### Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

---

**Results analysis stage**

---

Analysis stage	Final
Date of interim/final analysis	01 July 2015
Is this the analysis of the primary completion data?	Yes
Primary completion date	23 June 2015
Global end of trial reached?	Yes
Global end of trial date	30 June 2015
Was the trial ended prematurely?	No

Notes:

---

**General information about the trial**

---

Main objective of the trial:

To investigate whether clonidine as an adjuvant to ropivacaine for adductor canal block increases duration of the sensory block when controlling for a systemic effect

Protection of trial subjects:

All nerve blocks were performed by a trained anesthesiologist

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	01 March 2015
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

---

**Population of trial subjects**

---

**Subjects enrolled per country**

Country: Number of subjects enrolled	Denmark: 42
Worldwide total number of subjects	42
EEA total number of subjects	42

Notes:

---

**Subjects enrolled per age group**

---

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	42
From 65 to 84 years	0
85 years and over	0

## Subject disposition

### Recruitment

Recruitment details:

Patients very healthy volunteers recruited in the medical School of Copenhagen's medical bulletin.

### Pre-assignment

Screening details:

Eligible volunteers were males, more than 18 years old, and had American Society of Anesthesiologists physical status I. Exclusion criteria were inability to read and speak Danish, allergies to the involved drugs, weekly alcohol consumption of more than 21 units, medical abuse, use of any analgesics within 48 h or consumption of opioids within

### Period 1

Period 1 title	Baseline
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator, Monitor, Data analyst, Carer, Assessor

### Arms

Are arms mutually exclusive?	Yes
<b>Arm title</b>	Ropi + clonidine

Arm description: -

Arm type	Experimental
Investigational medicinal product name	Clonidine
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Perineural use

Dosage and administration details:

100ug perineurally co-administered with ropivacaine

<b>Arm title</b>	Ropivacaine + placebo
------------------	-----------------------

Arm description: -

Arm type	Placebo
Investigational medicinal product name	saline
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Perineural use

Dosage and administration details:

1 ml saline

Number of subjects in period 1	Ropi + clonidine	Ropivacaine + placebo
Started	21	21
Completed	21	21

## Period 2

Period 2 title	Overall trial
Is this the baseline period?	No
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator, Monitor, Data analyst, Carer, Assessor

## Arms

Are arms mutually exclusive?	Yes
<b>Arm title</b>	ropivacaine + clonidine

Arm description: -

Arm type	Experimental
Investigational medicinal product name	Clonidine
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Perineural use

Dosage and administration details:

100ug perineurally co-administered with ropivacaine

<b>Arm title</b>	Ropivacaine + placebo
------------------	-----------------------

Arm description: -

Arm type	Placebo
Investigational medicinal product name	saline
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Perineural use

Dosage and administration details:

1 ml saline

Number of subjects in period 2	ropivacaine + clonidine	Ropivacaine + placebo
Started	21	21
Completed	21	21



## Baseline characteristics

### Reporting groups

Reporting group title	Baseline
-----------------------	----------

Reporting group description: -

Reporting group values	Baseline	Total	
Number of subjects	42	42	
Age categorical			
Units: Subjects			
In utero		0	
Preterm newborn infants (gestational age < 37 wks)		0	
Newborns (0-27 days)		0	
Infants and toddlers (28 days-23 months)		0	
Children (2-11 years)		0	
Adolescents (12-17 years)		0	
Adults (18-64 years)		0	
From 65-84 years		0	
85 years and over		0	
Age continuous			
Units: years			
arithmetic mean	23		
standard deviation	± 2	-	
Gender categorical			
Units: Subjects			
Female	0	0	
Male	42	42	

## End points

### End points reporting groups

Reporting group title	Ropi + clonidine
Reporting group description: -	
Reporting group title	Ropivacaine + placebo
Reporting group description: -	
Reporting group title	ropivacaine + clonidine
Reporting group description: -	
Reporting group title	Ropivacaine + placebo
Reporting group description: -	

### Primary: duration of sensory nerve block assessed by temperature discrimination

End point title	duration of sensory nerve block assessed by temperature discrimination
End point description:	
End point type	Primary
End point timeframe:	0-48h

End point values	ropivacaine + clonidine	Ropivacaine + placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	21	21		
Units: hours				
arithmetic mean (confidence interval 95%)	19.4 (18.2 to 20.6)	19.3 (18.2 to 20.4)		

### Statistical analyses

Statistical analysis title	paired t test
Comparison groups	Ropivacaine + placebo v ropivacaine + clonidine
Number of subjects included in analysis	42
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.05
Method	t-test, 2-sided

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

0-48h

Assessment type	Non-systematic
-----------------	----------------

### Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	1
--------------------	---

### Reporting groups

Reporting group title	all participants
-----------------------	------------------

Reporting group description: -

<b>Serious adverse events</b>	all participants		
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 42 (0.00%)		
number of deaths (all causes)	0		
number of deaths resulting from adverse events	0		

Frequency threshold for reporting non-serious adverse events: 1 %

<b>Non-serious adverse events</b>	all participants		
Total subjects affected by non-serious adverse events			
subjects affected / exposed	4 / 42 (9.52%)		
Cardiac disorders			
bradycardia			
subjects affected / exposed	3 / 42 (7.14%)		
occurrences (all)	3		
Musculoskeletal and connective tissue disorders			
fall			
subjects affected / exposed	1 / 42 (2.38%)		
occurrences (all)	1		



## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? No

---

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

None reported

---

### Online references

<http://www.ncbi.nlm.nih.gov/pubmed/28880902>